Company intelligence / Profile preview

DNA Polymerase Technology

St Louis, Missouri, United Statesklentaq.com ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

DNA Polymerase Technology has developed several proprietary enzyme technologies that improve the fidelity, speed, inhibitor resistance, and specificity of the polymerase chain reaction. Their products are commercially available and widely used in research settings. No clinical results as they do not develop therapeutics.

Modalities: Enzymes for PCR (Polymerases)molecular biology reagents
Industry: Non-Drug Biotech

Drug pipeline

3 assets

Klentaq

Commercial

Indications: PCR applications

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on DNA Polymerase Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA Polymerase Technology.

Explore the full profile